Jianjin Huang

745 total citations
25 papers, 338 citations indexed

About

Jianjin Huang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jianjin Huang has authored 25 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Jianjin Huang's work include Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Jianjin Huang is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Jianjin Huang collaborates with scholars based in China, Taiwan and United Kingdom. Jianjin Huang's co-authors include Ling Ding, Pan Chi, Shu Zheng, Yanyan Xuan, Hanguang Hu, Qi Zhang, Jianzhen Shan, Wei Chen, Xiaochen Wang and Lifeng Sun and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jianjin Huang

25 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianjin Huang China 11 134 117 105 81 44 25 338
Samira Syed United States 11 122 0.9× 151 1.3× 55 0.5× 94 1.2× 41 0.9× 37 390
Xinchang Lu China 12 200 1.5× 99 0.8× 111 1.1× 94 1.2× 37 0.8× 25 376
Yoshinori Doki Japan 12 179 1.3× 209 1.8× 151 1.4× 88 1.1× 117 2.7× 40 544
Wenjun Jiang China 14 224 1.7× 49 0.4× 66 0.6× 92 1.1× 49 1.1× 20 380
Catherine J. Drummond United Kingdom 14 248 1.9× 159 1.4× 93 0.9× 66 0.8× 17 0.4× 24 452
Chenghui Huang China 12 164 1.2× 71 0.6× 40 0.4× 113 1.4× 54 1.2× 37 428
Lin-ang Wang China 11 189 1.4× 111 0.9× 76 0.7× 117 1.4× 56 1.3× 17 356
Shigeto Nishikawa Japan 10 171 1.3× 112 1.0× 78 0.7× 96 1.2× 53 1.2× 31 353

Countries citing papers authored by Jianjin Huang

Since Specialization
Citations

This map shows the geographic impact of Jianjin Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianjin Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianjin Huang more than expected).

Fields of papers citing papers by Jianjin Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianjin Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianjin Huang. The network helps show where Jianjin Huang may publish in the future.

Co-authorship network of co-authors of Jianjin Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Jianjin Huang. A scholar is included among the top collaborators of Jianjin Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianjin Huang. Jianjin Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Yuxiang, Yu Liu, Yang Zhang, et al.. (2022). Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. Journal of Thoracic Disease. 14(12). 4751–4762. 10 indexed citations
2.
Song, Zhengbo, Dongqing Lv, Shiqing Chen, et al.. (2021). Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clinical Cancer Research. 28(3). 461–467. 31 indexed citations
3.
Chen, Wei, Zhouqi Li, Hao Liu, et al.. (2020). MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib. Cell Death and Disease. 11(3). 198–198. 51 indexed citations
4.
Zhang, Wen, Yiping Zhang, Qiong Zhao, et al.. (2020). Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease. 12(3). 639–650. 7 indexed citations
5.
Zhao, Hongyun, Yuxiang Ma, Yang Zhang, et al.. (2020). Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study. Cancer Research. 80(16_Supplement). 579–579. 1 indexed citations
6.
7.
Jian, Hong, Wěi Li, Zhiyong Ma, et al.. (2017). Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports. 7(1). 8483–8483. 6 indexed citations
8.
Shan, Jianzhen, Yanyan Xuan, Qi Zhang, & Jianjin Huang. (2016). Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α. Journal of Zhejiang University SCIENCE B. 17(9). 672–682. 32 indexed citations
9.
Zhao, Jing, Hong Shen, Hanguang Hu, & Jianjin Huang. (2015). Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World Journal of Gastroenterology. 21(11). 3441–3446. 2 indexed citations
10.
He, Jianxing, Yuankai Shi, Jianhua Chang, et al.. (2015). An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 33(15_suppl). 8039–8039. 3 indexed citations
11.
Chi, Pan, Jun Li, Zhaoyi Wang, et al.. (2014). Estrogen Receptor-α36 Is Involved in Pterostilbene-Induced Apoptosis and Anti-Proliferation in In Vitro and In Vivo Breast Cancer. PLoS ONE. 9(8). e104459–e104459. 31 indexed citations
12.
Yuan, Ying, Xiaofen Li, Jiaqi Chen, et al.. (2014). Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. OncoTargets and Therapy. 7. 841–841. 14 indexed citations
13.
Huang, Jianjin, Pan Chi, Hanguang Hu, Shu Zheng, & Ling Ding. (2012). Osteopontin-Enhanced Hepatic Metastasis of Colorectal Cancer Cells. PLoS ONE. 7(10). e47901–e47901. 39 indexed citations
14.
Huang, Jianjin, Yu‐Jen Hsiao, Te‐Hua Fang, & Tao‐Hsing Chen. (2012). Synthesis and characterization of nanostructured Ba5Ta4O15 by sol–gel process. Journal of Sol-Gel Science and Technology. 62(1). 75–78. 6 indexed citations
15.
Zhang, Xiaodong, Yongqian Shu, Jun Liang, et al.. (2012). Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chinese Journal of Cancer Research. 24(4). 291–298. 11 indexed citations
16.
Fu, Xianhua, ­Jun Li­, Yong Zou, et al.. (2011). Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Letters. 312(1). 109–116. 20 indexed citations
17.
Tian, Weihua, Zhi‐Qiang Wang, Shucai Zhang, et al.. (2010). Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Medical Oncology. 28(1). 71–78. 21 indexed citations
18.
Dong, Ying, Dong Liang, Jianjin Huang, & Peng Zhang. (2009). Sesquiterpenes with Quinone Reductase-Inducing Activity from Liriodendron Chinense. Natural Product Communications. 4(4). 467–8. 2 indexed citations
19.
Huang, Jianjin. (2009). Effect of Diyushengbai Tablet on Blood Cell Decreasing During Chemotherapy of Non-small Cell Lung Cancer. 1 indexed citations
20.
Guan, Zhong-Zhen, Feng-yi Feng, Zefei Jiang, et al.. (2009). Superior efficacy of a Cremophor‐free albumin‐bound paclitaxel compared with solvent‐based paclitaxel in Chinese patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology. 5(3). 165–174. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samira Syed Breakdown of academic impact, for papers by Xinchang Lu Breakdown of academic impact, for papers by Yoshinori Doki Breakdown of academic impact, for papers by Wenjun Jiang Breakdown of academic impact, for papers by Catherine J. Drummond Breakdown of academic impact, for papers by Chenghui Huang Breakdown of academic impact, for papers by Lin-ang Wang Breakdown of academic impact, for papers by Shigeto Nishikawa
Rankless by CCL
2026